Navigation Links
Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
Date:6/22/2011

BANGALORE, India, June 23, 2011 /PRNewswire/ --


 

Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area.

The collaboration, initiated two years ago in the Neuroscience therapeutic area, has now expanded to Cardiovascular and Metabolic diseases and focuses on the delivery of a steady stream of preclinical outcomes to AstraZeneca, by Jubilant. AstraZeneca owns the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development,Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant said: "We are pleased that we have delivered outcomes and early success to the portfolio efforts at AstraZeneca.  This is the result of excellent collaboration between scientists at Jubilant and AstraZeneca.

"Partnering is a strategic priority for AstraZeneca at all stages of drug discovery and development," says Christof Angst, CNS & Pain Innovative Medicines, Vice-President, Strategy and Externalisation. "By combining our strengths with those of our partners, we are in a better position to deliver new medicines that can make a meaningful difference to patients' lives."  

About Us  

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development   and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

http://www.astrazeneca.com

Contact For Business Queries

narendra_kumar@jubilantbiosys.com , +91-9611104886



'/>"/>
SOURCE Jubilant Biosys Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jubilant Enters Research Collaboration With AstraZeneca
2. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
5. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
9. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider ... the clinical trials market. Similar to its approach in demonstrating positive outcomes in the ... marketplace by proving the value of eVisits to support virtual studies. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... in Cincinnati, OH for leading-edge care, whether or not they have a referral. ... the BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting ...
(Date:6/20/2017)... JEFFERSON HILLS, PA (PRWEB) , ... June 20, ... ... now available at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with ... 1.5T, 48-channel scanner provides higher-resolution images than traditional MRIs, enabling doctors to get ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished Sun Corridor ... Program selected Wisdom Natural Brands (WNB), and 16 other businesses from Pima, Pinal, ...
(Date:6/20/2017)... ... 20, 2017 , ... BrightStar Care Centerville/South Dayton, a home ... Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs in ... symbol of quality that reflects an organization’s commitment to meeting certain performance standards. ...
Breaking Medicine News(10 mins):